A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

被引:0
作者
Dan G Duda
Kenneth S Cohen
David T Scadden
Rakesh K Jain
机构
[1] Steele Laboratory for Tumor Biology,Department of Radiation Oncology
[2] Massachusetts General Hospital,undefined
[3] Center for Regenerative Medicine,undefined
[4] Massachusetts General Hospital and Harvard Stem Cell Institute,undefined
来源
Nature Protocols | 2007年 / 2卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor cells (CPCs) represent two cell populations that are thought to play important roles in tissue vascularization. CECs and CPCs are currently studied as surrogate markers in patients for more than a dozen pathologies, including heart disease and cancer. However, data interpretation has often been difficult because of multiple definitions, methods and protocols used to evaluate and count these cells by different laboratories. Here, we propose a cytometry protocol for phenotypic identification and enumeration of CECs and CPCs in human blood using four surface markers: CD31, CD34, CD133 and CD45. This method allows further phenotypic analyses to explore the biology of these cells. In addition, it offers a platform for longitudinal studies of these cells in patients with different pathologies. The protocol is relatively simple, inexpensive and can be adapted for multiple flow cytometer types or software. The procedure should take 2–2.5 h, and is expected to detect 0.1–6.0% viable CECs and 0.01–0.20% CPCs within blood mononuclear cell population.
引用
收藏
页码:805 / 810
页数:5
相关论文
共 22 条
  • [1] Rafii S(2002)Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2 826-835
  • [2] Lyden D(2003)Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells Nat. Med. 9 1370-1376
  • [3] Benezra R(2006)The multifaceted circulating endothelial cell in cancer: towards marker and target identification Nat. Rev. Cancer 6 835-845
  • [4] Hattori K(2006)Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 24-40
  • [5] Heissig B(2001)Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res. 61 4341-4344
  • [6] Aicher A(2001)Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood 97 3658-3661
  • [7] Bertolini F(2006)Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy J. Clin. Oncol. 24 1449-1453
  • [8] Shaked Y(2007)Reply to: Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J. Clin. Oncol. 25 e3-e5
  • [9] Mancuso P(2004)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 145-147
  • [10] Kerbel RS(2005)Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J. Clin. Oncol. 23 8136-8139